Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).
Charles River Laboratories (CRL) Q3 CY2025 Highlights:
- Revenue: $1.00 billion vs analyst estimates of $994.2 million (flat year on year, 1.1% beat)
- Adjusted EPS: $2.43 vs analyst estimates of $2.34 (3.9% beat)
- Adjusted EBITDA: $255.5 million vs analyst estimates of $231 million (25.4% margin, 10.6% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $10.20 at the midpoint
- Operating Margin: 13.3%, up from 11.6% in the same quarter last year
- Organic Revenue fell 1.6% year on year vs analyst estimates of 2.5% declines (87.8 basis point beat)
- Market Capitalization: $8.25 billion
StockStory’s Take
Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing challenges in the biotech funding environment, which dampened demand from smaller clients, and the loss of a major commercial customer in the Manufacturing segment. CEO James Foster explained that “client demand has stabilized,” but acknowledged lingering end market uncertainty, particularly among mid-sized biotech customers who remain cautious amid funding constraints.
Looking forward, management believes that recent improvements in biotech funding and rising proposal activity could set the stage for a recovery in demand over the next year. The company is pursuing a strategy of portfolio refinement, with planned divestitures of underperforming assets and incremental cost savings targeted for 2026. Foster emphasized that “the initiatives we are taking to strengthen our portfolio, maximize our financial performance and maintain a disciplined capital allocation strategy will further strengthen our market position and lead to long-term shareholder value creation.”
Key Insights from Management’s Remarks
Management attributed the quarter’s results to stable demand trends, portfolio optimization efforts, and actions to improve operational efficiency, while acknowledging persistent headwinds in biotech funding and manufacturing.
- Strategic portfolio review: The company initiated a comprehensive review, resulting in a plan to divest underperforming and non-core businesses representing about 7% of annual revenue, with the goal of focusing on higher-margin, core growth areas.
- Operational cost savings: Charles River Laboratories continued implementing restructuring and efficiency initiatives, targeting $225 million in annualized cost reductions through 2026, complemented by an additional $70 million in process improvements such as procurement synergies and a global business services model.
- Segment-specific trends: The Research Models and Services (RMS) segment benefited from favorable timing of non-human primate (NHP) shipments, while the Discovery and Safety Assessment (DSA) segment saw demand and booking activity stabilize, supported by improved biotech funding in recent months.
- Manufacturing segment headwinds: Manufacturing revenue declined, primarily due to the wind-down of a large commercial cell therapy client and ongoing project delays in biologics testing. However, the Microbial Solutions subsegment reported robust growth, driven by demand for rapid endotoxin testing and microbial identification.
- New product and technology focus: The company highlighted ongoing investments in new approach methodologies (NAMs), including animal-free safety testing and next-generation sequencing, with growing but still early-stage client adoption supported by a newly established Scientific Advisory Board.
Drivers of Future Performance
Charles River Laboratories expects future performance to hinge on the pace of biotech funding recovery, operational efficiency initiatives, and portfolio realignment.
- Biotech funding and demand trends: Management sees recent improvements in capital markets as critical for boosting bookings from small and mid-sized biotech clients. CEO Foster noted that “biotech funding for October was the second highest month in the history of all of biotech,” which could translate to higher study volumes if sustained.
- Operational efficiency and cost discipline: The company aims to realize $100 million in incremental cost savings in 2026, through a combination of workforce optimization, procurement savings, and automation. These measures are designed to offset inflationary pressures and protect operating margins.
- Portfolio divestitures and capital allocation: Planned asset sales should improve earnings accretion and allow Charles River Laboratories to concentrate on core growth segments. Management will balance proceeds between acquisitions, share repurchases, and debt reduction, maintaining leverage below 3x EBITDA to support strategic flexibility.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) sustained improvement in biotech funding and its impact on DSA bookings and backlog; (2) progress on the planned divestiture of non-core businesses and realization of targeted cost savings; and (3) stabilization or growth in key segments such as Microbial Solutions and Research Models and Services. Execution on NAMs adoption and customer demand trends will remain important additional drivers.
Charles River Laboratories currently trades at $167.69, down from $177.90 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.